

1 September 2021

**Diaceutics PLC**  
**("Diaceutics" or "the Company")**

**PDMR Shareholding/Share Incentive Plan**

[Diaceutics PLC](#), (AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified that on 27 August 2021 Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Susanne Munksted and Damian Thornton (both PDMRs), in respect of their purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.

In accordance with the SIP Scheme, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.

**Enquiries:**

**Diaceutics PLC**  
Philip White, Chief Financial Officer

Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**  
Ben Maddison  
Stewart Wallace  
Nick Adams

Tel: +44 (0)20 7710 7600

**Alma PR**  
Caroline Forde  
Robyn Fisher  
Kieran Breheny

Tel: +44(0)20 3405 0205  
diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>		
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>		
a.	Name	Susanne Munksted
<b>2 Reason for notification</b>		
a.	Position/Status	Managing Director and PDMR
b.	Initial notification/ Amendment	Initial
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a.	Name	Diaceutics PLC

b.	LEI	213800VEWQBB39ZB8J81										
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>												
a.	Description of the financial instrument, type of instrument  Identification Code	Ordinary shares of £0.002 each  ISIN: GB00BJQTGV64										
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")										
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>113.00 p</td> <td>126</td> </tr> <tr> <td colspan="2">Conditional share award:</td> </tr> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> <tr> <td>Nil</td> <td>252</td> </tr> </tbody> </table>	Price(s)	Volume(s)	113.00 p	126	Conditional share award:		Price(s)	Volume(s)	Nil	252
Price(s)	Volume(s)											
113.00 p	126											
Conditional share award:												
Price(s)	Volume(s)											
Nil	252											
e.	Date of the transaction	Share purchase and Conditional share award: 27 August 2021										
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange  Conditional share award: Off-Market										

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>		
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>		
a.	Name	Damian Thornton
<b>2 Reason for notification</b>		
a.	Position/Status	Chief Operating Officer and PDMR
b.	Initial notification/ Amendment	Initial
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a.	Description of the financial instrument, type of instrument  Identification Code	Ordinary shares of £0.002 each  ISIN: GB00BJQTGV64
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares to matched by the grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP")

c.	Price(s) and volume(s)	<p>Share purchase:</p> <table border="1" data-bbox="507 188 927 528"> <tr> <td data-bbox="507 188 691 253">Price(s)</td> <td data-bbox="691 188 927 253">Volume(s)</td> </tr> <tr> <td data-bbox="507 253 691 318">113.00 p</td> <td data-bbox="691 253 927 318">130</td> </tr> <tr> <td colspan="2" data-bbox="507 318 927 383">Options:</td> </tr> <tr> <td data-bbox="507 383 691 448">Price(s)</td> <td data-bbox="691 383 927 448">Volume(s)</td> </tr> <tr> <td data-bbox="507 448 691 528">Nil</td> <td data-bbox="691 448 927 528">260</td> </tr> </table>	Price(s)	Volume(s)	113.00 p	130	Options:		Price(s)	Volume(s)	Nil	260
Price(s)	Volume(s)											
113.00 p	130											
Options:												
Price(s)	Volume(s)											
Nil	260											
e.	Date of the transaction	Share purchase and Option award: 27 August 2021										
f.	Place of the transaction	<p>Share Purchase: AIM Market of the London Stock Exchange</p> <p>Option award: Off-Market</p>										

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHDKDBQFBKDPFN